A genetic review of news from three studies suggests that genetically elevated levels of lipoprotein(a) are associated with an increased risk of passion attack, according to a study in the June 10 question of JAMA. Myocardial infarction (MI; emotions attack) remains a important end of illness and death despite targeting of low-density lipoprotein (LDL) cholesterol by statin therapy. "The itch for identification of supplementary causal factors, and thus potential new targets for prophylactic treatment, is apparent. Elevated levels of lipoprotein(a) [a LDL particle bound to a plasminogen-like glycoprotein, apolipoprotein(a)] represent such a candidate; however, whether lipoprotein(a) causes MI is unclear.
Abbott and AstraZeneca announced nowadays that they have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX ® (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca testament acquire the non-exclusive prerrogative to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Particular financial terms were not disclosed. "Abbott's portfolio of lipid therapies is designed to help physicians manage a patient's complete lipid profile, " said Jeffrey Stewart, divisional vise president, Essential Care, Abbott.
Abbott And AstraZeneca Submit New Narcotic Exercise To The FDA For CERTRIAD trade;, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies annex submitted a New Drug Application (NDA) to the U.S. Chow and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or extended lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR ® (rosuvastatin calcium) and TRILIPIX ® (fenofibric acid), is supported by counsel from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid.
Small LDL (sLDL) is the most harmful appearance of cholesterol! People with small LDL are five times as imaginable to have cardiovascular disease. However, most laboratories arrange not test for it. Randox provides an cinch to practice sLDL test to avail assess cardiovascular disease risk. Early identification of predominant sLDL can cooperation clinicians coerce patients more effectively terminated enhanced aggressive treatment. The test is available from Randox, and is for bag on automated analysers and is no and difficult to use than a sample cholesterol test. This testament by-product in discount in costs and will save lives. Randox sLDL tests retain regulate clearance methodologies removing non-sLDL particles in the initial pre-treatment step.
A new lozenge that contains a potent version of the naturally occurring compound lycopene, a carotenoid found in tomatoes and other fruits and vegetables, was launched nowadays as a new avenue to the treatment of high blood cholesterol and atherosclerosis. The new pill, called Ateronon, is false by Cambridge Theranostics, a bio-technology spin-out of Cambridge University, in the UK, and was launched today, Monday, at a convention of the British Cardiovascular Country in London. It is described by its manufacturer as a "one-a-day" natural supplement that is clinically proven to help inhibit the oxidation of LDL or "bad" cholesterol. This is important, they said, because when LDL cholesterol is oxidized it causes atherosclerosis, where plaque builds up inside arteries and causes them to "fur up".
Abbott And AstraZeneca Submit Virgin Narcotic Practice To The FDA For CERTRIAD TM , An Investigational Treatment For Mixed Dyslipidemia
Abbott (NYSE: ABT) and AstraZeneca announced that the companies carry submitted a Different Drug Application (NDA) to the U.S. Cookery and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including colossal LDL- cholesterol (the "bad" cholesterol), flying triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR(R) (rosuvastatin calcium) and TRILIPIX(R) (fenofibric acid), is supported by counsel from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid.
Overweight individuals who ate a low-calorie, low-carbohydrate diet hovering in plant-based proteins for four weeks lost weight and experienced improvements in blood cholesterol levels and other heart disease risk factors, according to a report in the June 8 matter of Archives of Internal Medicine, one of the JAMA/Archives journals. A high-carbohydrate, low-fat vegetarian diet also resulted in weight loss but without the additional cardiovascular benefits. "There is a dilemma relating to the proportion and source of fat, protein and carbohydrate that constitutes the optimal weight loss and cholesterol-lowering diet, " the authors bang out as background information in the article.
The atherosclerosis vaccine transaction programme by AFFiRiS AG is receiving financial bed from the EU's EUROTRANS-BIO call. The respective project is existence carried gone in cooperation with German company EMC microcollections GmbH. The speck of atherosclerosis vaccination is to increase the proportions of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus diminish the incident of harmful fatty deposits in the arteries. Product candidates were delivered by AFFiRiS' AFFITOME® platform technology. The target is a protein hackneyed as CETP (cholesteryl ester transfer protein). Next vaccines for Alzheimer¬ s disease and Parkinson's disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS AG.
Patients newly diagnosed with hypertension, diabetes or high cholesterol are significantly more likely to delay initiating recommended drug treatment provided they face higher co-payments for medications, according to a brand-new RAND Collection study. The delay was forceful across all conditions, but the impact was largest among patients who had not previously used prescription drugs, according to the study published in the Apr 27 edition of the Archives of Internal Medicine. While distinct studies have established that higher narcotic co-payments discourage some patients from captivating their medications, the new RAND Health discover is the ahead to examine the impact higher out-of-pocket costs hold on patients who are creation drug treatment after growth diagnosed with a chronic illnesses.
Flying Co-Payments Associated With Delay In Starting Narcotic Therapy In Patients With Chronic Diseases
High co-payments are associated with delayed initiation of medication in patients with newly diagnosed hypertension, diabetes and elevated cholesterol levels, according to a report in the Apr 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Rising prescription drug costs in the past decade keep caused else restrictive insurance benefits, including an development in value sharing (i.e., 'co-payments'), multi-tier formularies and binding generic substitution, according to background enlightenment in the article. "Several studies have demonstrated that these new arrangements lessen overall drug utilization and expenditures and that the chronically sick are touchy to out-of-pocket costs.